Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update


ISELIN, N.J., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced financial results for fiscal year 2024 and provided a corporate update.

See the rest here:
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Related Posts